Evidence map›Paper›PMID 37903679›Full record

ArticleVaccine2023

Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines.

Yi Liu, Stephany Sánchez-Ovando, Louise Carolan, Leslie Dowson, Arseniy Khvorov, A Jessica Hadiprodjo, Yeu Yang Tseng, Catherine Delahunty, Ameneh Khatami, Marion Macnish and 20 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05110911 (Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05110911 active not recruitingnot on this map

Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection

TypeobservationalSponsorUniversity of MelbourneRan2020 to 2025Enrolled1,500ConditionsInfluenza, Human, SARS-CoV-2 InfectionArmsInfluenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad, SARS-CoV-2 vaccination: Comirnaty or Vaxzevria
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 11 institutions in 2 countries.

Yi LiuDepartment of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Stephany Sánchez-OvandoDepartment of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Louise CarolanWHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Leslie DowsonDepartment of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Arseniy KhvorovDepartment of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
A Jessica HadiprodjoDepartment of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Yeu Yang TsengDepartment of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Catherine DelahuntyImmune Health Program, Hunter Medical Research Institute and School of Medicine and Public Health, University of Newcastle, Newcastle, Australia.
Ameneh KhatamiThe Children's Hospital at Westmead, Sydney Children's Hospital Network, National Centre for Immunisation Research and Surveillance, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia.
Marion MacnishWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia.
Sonia DoughertyQueensland Children's Hospital, Children's Health Queensland Hospital and Health Service, and University of Queensland, Brisbane, Australia.
Michelle HagenauerAlfred Health, Monash Health and Monash University, Melbourne, Australia.
Kathryn E RileyAdelaide Medical School and Robinson Research Institute, The University of Adelaide, Adelaide, Australia; Division of Paediatric Medicine, Women's and Children's Health Network, Adelaide, Australia.
Ajay JadhavThe Children's Hospital at Westmead, Sydney Children's Hospital Network, National Centre for Immunisation Research and Surveillance, Sydney, Australia.
Joanne HarveyWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia.
Marti KaiserAlfred Health, Monash Health and Monash University, Melbourne, Australia.
Suja MathewAdelaide Medical School and Robinson Research Institute, The University of Adelaide, Adelaide, Australia; Division of Paediatric Medicine, Women's and Children's Health Network, Adelaide, Australia.
David HodgsonDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Vivian LeungDepartment of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Kanta SubbaraoDepartment of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Allen C ChengAlfred Health, Monash Health and Monash University, Melbourne, Australia.
Kristine MacartneyThe Children's Hospital at Westmead, Sydney Children's Hospital Network, National Centre for Immunisation Research and Surveillance, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia.
Archana KoiralaThe Children's Hospital at Westmead, Sydney Children's Hospital Network, National Centre for Immunisation Research and Surveillance, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia.
Helen MarshallAdelaide Medical School and Robinson Research Institute, The University of Adelaide, Adelaide, Australia; Division of Paediatric Medicine, Women's and Children's Health Network, Adelaide, Australia.
Julia ClarkQueensland Children's Hospital, Children's Health Queensland Hospital and Health Service, and University of Queensland, Brisbane, Australia.
Christopher C BlythWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia; School of Medicine, University of Western Australia, Perth Children's Hospital, and Department of Microbiology, PathWest Laboratory Medicine, QEII medical centre, Perth, Australia.
Peter WarkImmune Health Program, Hunter Medical Research Institute and School of Medicine and Public Health, University of Newcastle, Newcastle, Australia.
Adam J KucharskiDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Sheena G SullivanDepartment of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; Department of Epidemiology, University of California, Los Angeles, USA.
Annette FoxDepartment of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia. Electronic address: annette.fox@unimelb.edu.au.
Peter Doherty Institute · AUMonash Health · AUSydney Children’s Hospitals Network · AUThe Kids Research Institute Australia · AUWomen's & Children's Health Research Institute · AUHunter Medical Research Institute · AULondon School of Hygiene & Tropical Medicine · GBThe University of Melbourne · AUThe University of Queensland · AUChildren's Hospital at Westmead · AUThe Royal Melbourne Hospital · AU

Funding

Does repeated influenza vaccination constrain influenza immune responses and protection?R01AI141534 · NIAID · UNIVERSITY OF MELBOURNE · PI FOX, ANNETTE, KUCHARSKI, ADAM JAMES · 2019 to 2023
$4.9M
NEURAL MECHANISM OF ATTENTIONAL CONTROL AND SELECTIONK05MH002019 · NIMH · UNIVERSITY OF CALIFORNIA DAVIS · PI MANGUN, GEORGE R · 2001 to 2005
$587k
NIAID NIH HHS R01 AI141534NIMH NIH HHS K05 MH002019
6 · The paper itself

Abstract

Both vector and mRNA vaccines were an important part of the response to the COVID-19 pandemic and may be required in future outbreaks and pandemics. The aim of this study was to validate whether immunogenicity differs for adenoviral vectored (AdV) versus mRNA vaccines against SARS-CoV-2, and to investigate how anti-vector immunity and B cell dynamics modulate immunogenicity. We enrolled SARS-CoV-2 infection-naïve health care workers who had received two doses of either AdV AZD1222 (n = 184) or mRNA BNT162b2 vaccine (n = 274) between April and October 2021. Blood was collected at least once, 10-48 days after vaccine dose 2 for antibody and B cell analyses. Median ages were 42 and 39 years, for AdV and mRNA vaccinees, respectively. Surrogate virus neutralization test (sVNT) and spike binding antibody titres were a median of 4.2 and 2.2 times lower, respectively, for AdV compared to mRNA vaccinees (p < 0.001). Median percentages of memory B cells that recognized fluorescent-tagged spike and RBD were 2.9 and 8.3 times lower, respectively for AdV compared to mRNA vaccinees. Titres of IgG reactive with human adenovirus type 5 hexon protein rose a median of 2.2-fold after AdV vaccination but were not correlated with anti-spike antibody titres. Together the results show that mRNA induced substantially more sVNT antibody than AdV vaccine, which reflected greater B cell expansion and targeting of the RBD rather than an attenuating effect of anti-vector antibodies. ClinicalTrials.gov Identifier: NCT05110911.

Indexed as

COVID-19Viral VaccinesAntibodiesAntibodies, ViralBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesHumansPandemicsSARS-CoV-2AntibodiesAntibodies, ViralBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesViral VaccinesAntibodyB cellsCOVID-19mRNASARS-CoV-2VaccineVector

Identifiers

PMID37903679
PMCPMC12571492
OpenAlexW4388035449

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.